As Head of Chemistry, Manufacturing, and Controls (CMC), Rob is responsible for API process development, formulation development, and manufacturing for Zehna’s programs.
Rob has over 15 years of broad experience in process chemistry, formulation development, scale-up, and GMP manufacturing across all stages of clinical development. Prior to Zehna, Rob held positions of increasing responsibility within CMC at Yumanity Therapeutics, Navitor Pharmaceuticals, and Concert Pharmaceuticals, overseeing pharmaceutical development both internally and externally. Rob led CMC activities for several early-stage programs that were acquired by major pharmaceutical companies, as well as API process development and manufacturing in the collaboration between Navitor and Supernus for the NV-5138 (SPN-820) program for treatment-resistant depression.
Rob began his career at Hovione LLC, gaining hands-on experience in solving a wide variety of process development and manufacturing challenges. Originally from New Jersey, Rob earned his BS in Chemistry from The College of New Jersey and PhD in organic chemistry from Princeton University.